Literature DB >> 17476342

Harnessing the immune system to treat cancer.

Nina Bhardwaj1.   

Abstract

A major challenge for the immune system is to recognize and eliminate cells undergoing carcinogenesis. Immune defense against tumors is complex. It can be mediated early by the innate immune system (i.e., phagocytes, NK cells, NKT cells, cytokines, and complement proteins) and later by the adaptive immune system (i.e., B cells and T cells). The eight articles in this Review series on tumor immunology discuss the mechanisms underlying immune surveillance of tumors, the regulation of carcinogenesis by immune inflammatory mediators, current approaches to controlling tumor growth through immunotherapy, and novel targets of immunotherapy.

Entities:  

Mesh:

Year:  2007        PMID: 17476342      PMCID: PMC1857237          DOI: 10.1172/JCI32136

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  120 in total

Review 1.  Thymic development and peripheral homeostasis of regulatory T cells.

Authors:  Adrian Liston; Alexander Y Rudensky
Journal:  Curr Opin Immunol       Date:  2007-02-15       Impact factor: 7.486

2.  Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.

Authors:  A J Schottelius; M W Mayo; R B Sartor; A S Baldwin
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

3.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Authors:  I Melero; W W Shuford; S A Newby; A Aruffo; J A Ledbetter; K E Hellström; R S Mittler; L Chen
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

4.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 5.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 6.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice.

Authors:  R K Sellon; S Tonkonogy; M Schultz; L A Dieleman; W Grenther; E Balish; D M Rennick; R B Sartor
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

Review 10.  Tumors of the immunocompromised patient.

Authors:  I Penn
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739

View more
  50 in total

Review 1.  The response of human dendritic cells to co-ligation of pattern-recognition receptors.

Authors:  Tanja Dzopalic; Ivan Rajkovic; Ana Dragicevic; Miodrag Colic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Impacts of K562 cells towards activities of Toll-like receptor pathway of human mesenchymal stem cell-bone marrow.

Authors:  Zheng Xu; Jianmin Luo; Lin Yang; Xingzhe Wang; Yuxia Pan; Yintao Shang; Jingci Yang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 3.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

4.  TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity.

Authors:  Dusan Bogunovic; Olivier Manches; Emmanuelle Godefroy; Alice Yewdall; Anne Gallois; Andres M Salazar; Isabelle Marie; David E Levy; Nina Bhardwaj
Journal:  Cancer Res       Date:  2011-07-05       Impact factor: 12.701

5.  Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer.

Authors:  Panagiotis Balermpas; Franz Rödel; Christian Weiss; Claus Rödel; Emmanouil Fokas
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

6.  Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.

Authors:  Janis V de la Iglesia; Robbert J C Slebos; Laura Martin-Gomez; Xuefeng Wang; Jamie K Teer; Aik Choon Tan; Travis A Gerke; Garrick Aden-Buie; Tessa van Veen; Jude Masannat; Ritu Chaudhary; Feifei Song; Michelle Fournier; Erin M Siegel; Matthew B Schabath; J Trad Wadsworth; Jimmy Caudell; Louis Harrison; Bruce M Wenig; Jose Conejo-Garcia; Juan C Hernandez-Prera; Christine H Chung
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

7.  Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion.

Authors:  S Peter; G Bak; Kevin Hart; Brent Berwin
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

Review 8.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

9.  Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.

Authors:  W M Liu; D W Fowler; P Smith; A G Dalgleish
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

10.  CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.

Authors:  Alice W Yewdall; Scott B Drutman; Felecia Jinwala; Keith S Bahjat; Nina Bhardwaj
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.